gip/glp-1 receptor agonist New strategies for the treatment of obesity and metabolic dysfunctions PDB-101: Molecule of the Month:

SID-AMD joint panel for Italian Guidelines on Treatment of Type 2 Diabetes Cardiovascular Events and All-Cause Mortality in Patients with Type 2 Diabetes Treated with Dipeptidyl Peptidase-4 Inhibitors: An Extensive Meta-Analysis of Randomized Controlled Trials

In the UK, the drug was approved in 2007

Spielman LJ, Gibson DL, Klegeris A

Lancet Diabetes Endocrinol 6(4):275286 Rossing P, Baeres FMM, Bakris G, Bosch-Traberg H, Gislum M, Gough SCL et al (2023) The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease

However, the underlying mechanism has not been fully elucidated